Retinal and Choroidal Imaging for Parkinson's (NCT03233646)
Eye imaging detects early Parkinson
- Trial ID
- NCT03233646
- Official Title
- Evaluating the Retinal and Choroidal Microvasculature and Structure Using Multimodal Retinal and Choroidal Imaging in Neurodegenerative Disease: iMIND Research Study
- Goal
- Eye imaging detects early Parkinson
- Status
- RECRUITING
- Sponsor
- Duke University
- Study Type
- OBSERVATIONAL
- Enrollment
- 2000 participants
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, Multiple Sclerosis, Huntington Disease, Lewy Body Dementia, Frontotemporal Dementia, Amyotrophic Lateral Sclerosis (ALS), APOE-4 Positive, Traumatic Brain Injury, Concussion, Post-Traumatic Stress Disorder, Down Syndrome, Neuro-Degenerative Disease, Normal Cognition
- Interventions
- Retinal and Choroidal Imaging
Summary For Families
Researchers want to find eye-based signs that reflect, or even come before, the small-vessel and tissue changes in the brain that happen with Parkinson's and other neurodegenerative diseases, so these conditions might be detected earlier. They use non-invasive eye scans, optical coherence tomography, optical coherence tomography angiography, and ultra-widefield fundus photography, to take detailed pictures of the retinal and choroidal blood vessels and tissue, then apply advanced image analysis and machine learning to look for reduced capillary blood flow, areas without blood flow, and structural changes. The team hopes these imaging markers, combined with known retinal signs, could become a useful screening tool during cognitive aging. Adults 18 and older can join, whether they have Parkinson's or another listed condition or are without neurodegenerative disease, as long as they can complete the eye scans and do not have eye problems or prior eye surgery (other than cataract surgery) that would prevent good imaging.
Locations
- Duke University Medical Center, Durham, North Carolina, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Retinal and Choroidal Imaging. Researchers want to find eye-based signs that reflect, or even come before, the small-vessel and tissue changes in the brain that happen with Parkinson's and other neurodegenerative diseases, so these conditions might be detected earlier. They use non-invasive eye scans, optical coherence tomography, optical coherence tomography angiography, and ultra-widefield fundus photography, to take detailed pictures of the retinal and choroidal blood vessels and tissue, then apply advanced image analysis and machine learning to look for reduced capillary blood flow, areas without blood flow, and structural changes. The team hopes these imaging markers, combined with known retinal signs, could become a useful screening tool during cognitive aging. Adults 18 and older can join, whether they have Parkinson's or another listed condition or are without neurodegenerative disease, as long as they can complete the eye scans and do not have eye problems or prior eye surgery (other than cataract surgery) that would prevent good imaging.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- You are never charged a fee to join a legitimate clinical trial, and the study treatment and study-specific tests are provided by the trial sponsor at no charge. In the US, routine care you would receive anyway can still be billed to you or your insurance; coverage rules differ by country, and trials in the UK and Canada usually run through public health systems. Travel, parking, and time are real costs, and some trials reimburse them while others do not. Before enrolling, ask the study coordinator to explain in writing what is and is not covered.
- How long does the trial last?
- This trial is estimated to last approximately 9 years and 5 months.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
- Will I get a placebo in this trial?
- This is an observational study, so there is no placebo and no experimental treatment is assigned. Researchers observe and collect information while you continue your usual care.